- Compare UK Investments
- Where To Invest
- Trade Shares
- Trade FTSE100 Shares
- Trade FTSE250 Shares
- Trade AIM Shares
- Trade European Shares
- Trade DJ30 Shares
- Trade S&P500 Shares
- Trade Forex
- Trade Commodities
- Trade Energy Commodities
- Trade Metal Commodities
- Trade Soft Commodities
- Recommended Financial Spread Betting Books
Trade AstraZeneca Shares
|
|||||||||||||||||||||||||||||||||||||
AstraZeneca and Market Latest NewsYahoo! Finance: AZN.L NewsFTSE lower as weak banks offset upbeat UK results (Reuters MOLT) FTSE lower as weak banks offset upbeat UK results (Other) European close: Stocks slump in afternoon session (ShareCast) European bourses turned around and headed lower in the afternoon session as a weak start on Wall Street overshadowed a string of good company results.
Market overview: Footsie gives up gains (ShareCast)1630: Close Footsie closed slightly in the red, despite starting well on the back of well-received company updates, as weakness in the US spread across the Atlantic.
NEWSMAKER-Sanofi's new broom CEO gets serious on M&A (Other)London afternoon: Footsie off the top (ShareCast) The Footsie drifted lower over the lunch time session though still remained in positive territory, thanks in large part to enthusiastic responses to results from heavy hitters AstraZeneca, BT and Reed Elsevier.
AstraZeneca doubles share buy-back plan [at Financial Times] (FT Times)AstraZeneca has upgraded earnings forecasts following strong US expert endorsement of its new drug Brilinta, as it pledged increased share buy-backs and unveiled strong second-quarter results.
Market overview: FTSE 100 up 33 (ShareCast)1520: Footsie remains buoyant as company updates impress the market. Business publisher Reed Elsevier, drug group AstraZeneca, miner Kazakhmys, telecoms group BT and Pearson, the publisher of the Financial Times, are among the top 10 risers in the FTSE 100 today after making announcements. Can maker Rexam is down for the second day in a row after yesterday's poorly received results. Tullow Oil, which jumped yesterday after another find, gives back some gains. FTSE 100 up 33 at 5,353.
FTSE 100 movers: Results push market higher (ShareCast)A raft of good results has boosted Footsie today.
Results Round Up (ShareCast)Royal Dutch Shell has trumped forecasts with a 15% jump in second quarter profit, in stark contrast to loss-making rival BP, thanks to higher oil prices and an increase in production.
TechMARK movers: Lack of revenue visibility at Torotrak (ShareCast)Torotrak has warned that the outcome for the year to March 2011 is still reliant on potential licence discussions and whether Allison transmission takes-up further options.
Market overview: FTSE 100 up 32 (ShareCast)1400: Business publisher Reed Elsevier, drug group AstraZeneca, miner Kazakhmys, telecoms group BT and Pearson, the publisher of the Financial Times, are among the top 10 risers in the FTSE 100 today after making announcements. Can maker Rexam is down for the second day in a row after yesterday's poorly received results. FTSE 100 up 32 at 5,353.
AstraZeneca doubles buyback as Brilinta shines (Reuters MOLT)BREAKINGVIEWS-Thanks for the profits. Now where's the growth? (Other) European midday: Earnings provide lift (ShareCast) A bunch of forecast beating corporate results are giving Europe's leading exchanges a lift in midday dealings.
Strong earnings help Europe shares revive rally (Other)WRAPUP 1-Sanofi seeks Genzyme fix, Astra gets new drug lift (Other) Market overview: FTSE 100 up 38 (ShareCast) 1215: The leading share index is firmly in the blue following a good reception for company updates. Business publisher Reed Elsevier is the top riser after saying advertising markets are stabilising. AstraZeneca has been given a shot in the arm by a US advisory panel backing its potential blockbuster heart drug Brilinta. FTSE 100 up 38 at 5,358.
Upbeat UK corporate earnings lift FTSE 100 (Reuters MOLT)After crisis, firms fuel spark of European optimism (Reuters MOLT) Copyright (c) 2010 Yahoo! Inc. All rights reserved.
|
|||||||||||||||||||||||||||||||||||||
AstraZeneca: Financial Spread Betting vs CFD vs Share DealingTable below compares Financial Spread Betting, Contract For Difference and Share Dealing trading. For simplicity we use the average brokerage fees to calculate the profit/loss if £1,000 available for investment in AstraZeneca shares (AstraZeneca share price is 3000p). Supposedly, you think that AstraZeneca shares will go up by 10% in one month.
|
|||||||||||||||||||||||||||||||||||||
AstraZeneca: Financial Spread Betting and Contracts For Difference (CFDs) are margined (or leveraged) products and let you go long (buy) or short (sell) with AstraZeneca shares, they are more suitable for short and medium term investments and cover a wide range of markets, including shares, indices, commodities and currencies. Share investing, on the other hand, is a conservative and old way of gaining financial independence and preserving capital. Even though some stockbrokers offer credit facilities it is very rare and not popular amongst private investors.
Risk Warning: Financial Spread Betting and Contracts For Difference (CFDs) are leveraged products and carry a high level of risk to your capital. You may lose more than your initial investment. Share price can go down as well as up and returns on investments are not guaranteed.